ADCOMS

AcronymDefinition
ADCOMSAdvanced Communications System
References in periodicals archive ?
Efficacy was analysed up to 18 months based on ADCOMS which combines items from the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS -Cog), the Clinical Dementia Rating Sum of Boxes (CDR-SB) scale and the Mini -Mental State Examination (MMSE) to enable sensitive detection of changes in early AD symptoms.
This dose also showed a statistically significant slowing of clinical decline on ADCOMS of 30 percent compared to placebo at 18 months (p=0.034).
The final analysis of the study demonstrated a statistically significant slowing of disease progression on the Alzheimer's disease composite score (ADCOMS) after 18 months of treatment in patients receiving the highest treatment dose of 10 mg/kg twice a month and reduction of amyloid accumulated in the brain as measured by using amyloid positron emission tomography (PET).
Efficacy was analysed up to 18 months based on ADCOMS, which integrates items from the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog), the Clinical Dementia Rating Sum of Boxes (CDR-SB) scale and the Mini-Mental State Examination (MMSE) to allow sensitive detection of changes in early Alzheimer's Disease symptoms.
The clinical endpoints of Alzheimer's Disease Composite Score (ADCOMS), Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) and Clinical Dementia Rating Sum of Boxes (CDR-SB) were also assessed from baseline to 18 months of treatment.
Based on his analysis, the analyst believes that the two most important things to see next week are a sizeable effect on the ADCOMS - Alzheimer's Disease Composite Score - endpoint in the highest dose at 18 months and strong trends toward benefit, perhaps reaching statistical significance, on traditional cognitive measures that are sub-components of the combined ADCOMS endpoint.
Efficacy was evaluated at 18 months and demonstrated a statistically significant slowing of disease progression on the Alzheimer's disease composite score (ADCOMS) after 18 months of treatment in patients receiving the highest treatment dose of 10 mg/kg twice a month and reduction of amyloid accumulated in the brain as measured by using amyloid positron emission tomography (PET).
The study achieved statistical significance on key predefined endpoints evaluating efficacy at 18 months on slowing progression in Alzheimers Disease Composite Score (ADCOMS) and on reduction of amyloid accumulated in the brain as measured using amyloid-PET (positron emission tomography).
The study achieved statistical significance on key predefined endpoints evaluating efficacy at 18 months on slowing progression in Alzheimer's Disease Composite Score (ADCOMS) and on reduction of amyloid accumulated in the brain as measured using amyloid-PET (positron emission tomography).
Further, a similar magnitude and direction of differential in decline was observed in a post-hoc analysis of ADCOMS, Eisai's newly developed assessment scale in the elenbecestat 50 mg total arm as compared to placebo.
Further, a similar magnitude and direction of differential in decline was observed in a post-hoc analysis of ADCOMS, Eisai's newly developed assessment scale (Alzheimer's Disease Composite Score) in the elenbecestat 50 mg total arm as compared to placebo.